A PYMNTS Company

U.S.: FTC places conditions on Watson’s acquisition of Actavis

By  |  October 16, 2012

The Federal Trade Commission (FTC) has required Watson Pharmaceuticals and Actavis Inc, both global pharmaceutical companies specializing in the development, production, and marketing of generic and branded drugs, to sell their rights and assets to 18 drugs to Sandoz International GmbH and Par Pharmaceuticals, Inc, and relinquish the manufacturing and marketing rights to three others, to settle charges that Watson’s proposed $5.9 billion acquisition of Actavis would otherwise be anticompetitive.

Full Content: FTC

Related Content: Watson Pharmaceutical confirms favorable ruling in antitrust litigation

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.